Suppression Effect of Ulva lactuca Selenium Nanoparticles (USeNPs) on HepG2 Carcinoma Cells Resulting from Degradation of Epidermal Growth Factor Receptor (EGFR) with an Evaluation of Its Antiviral and Antioxidant Activities

The current study sought to assess the antitumor, anticancer, and antioxidant efficacy of Ulva lactuca-mediated selenium nanoparticles by using an in vitro model human hepatocellular carcinoma (HepG-2 cells) HAV HM175 strain hepatitis A virus, with evaluation activity conducted DPPH assay. showed promising cytotoxicity at highest concentrations 250 500 µg/mL, viability rates 19.43 8.75% for cancer cells, lowest toxicity 59.41 30.64% normal respectively. These also exhibited inhibition (51.28 76.31%, respectively) against Epidermal Growth Factor Receptor (EGFR) enzyme provide explanation mechanism such cytotoxicity, as this is responsible degradation EGFR. Additionally, U. (USeNPs) antiviral (+++) (50–<75%) EC50 = 57.41 ?g/mL 74.13% 100 µg/mL maximum noncytotoxic conc (MNCC). Using MTT assay, its selectivity index was 5.78 ? 2, which indicates that USeNPs outweighed toxicity. Therefore, active agent warrants further study. Furthermore, scavenging moderate sample concentration (100 µg/mL) recorded 31.64 ± 0.03% (with IC50 158.02 0.07 ?g/mL), a percentage does not exceed standard ascorbic acid.